Screener
Krystal Biotech, Inc. KRYS Total Assets
Total Assets at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Assets.
The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 7:06 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001711279-26-000043
| (in thousands, except par value) | March 31,2026 | December 31,2025 |
|---|---|---|
| Right-of-use assets | 7,035 | 7,239 |
| Deferred tax asset, net of valuation allowance | 22,824 | 22,824 |
| Other non-current assets | 300 | 287 |
| Total assets | $1,396,967 | $1,333,794 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities | ||
| Accounts payable | $4,089 | $3,238 |
| Current portion of lease liability | 1,800 | 1,771 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Krystal Biotech, Inc.'s total assets?
- Krystal Biotech, Inc. (KRYS) reported total assets of $1.4B in Q1 2026.
- How has Krystal Biotech, Inc.'s total assets changed year-over-year?
- Krystal Biotech, Inc.'s total assets increased by 30.0% year-over-year, from $1.07B to $1.4B.
- What is the long-term trend for Krystal Biotech, Inc.'s total assets?
- Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s total assets has grown at a 33.8% compound annual growth rate (CAGR), from $310.84M to $1.33B.
- What does total assets mean?
- The sum of everything the company owns — current assets, property, investments, goodwill, intangibles, and all other assets.
Ask your AI about Krystal Biotech, Inc.'s total assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude